Erratum: Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis (Annals of the Rheumatic Diseases (2010) 69, (550-555) DOI:10.1136/ard.2009.116434);Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 69, Issue 3, 2010, Pages 550-555

  Gourh, Pravitt ^a   Arnett, Frank C ^a   Tan, Filemon K ^a   Assassi, Shervin ^a   Divecha, Dipal ^a   Paz, Gene ^a   McNearney, Terry ^b   Draeger, Hilda ^c   Reveille, John D ^a   Mayes, Maureen D ^a   Agarwal, Sandeep K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OX40 LIGAND;

ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS;

EID: 77949451240     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.116434corr1     Document Type: Erratum

References (51)

1. Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005;77:1044-60.
2. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009;360:1646-54.
3. Harley IT, Kaufman KM, Langefeld CD, et al. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 2009;10:285-90.
4. Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004;75:330-7.
5. Onengut-Gumuscu S, Ewens KG, Spielman RS, et al. A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type I diabetes in multiplex families. Genes Immun 2004;5:678-80.
6. Orozco G, Sánchez E, González-Gay MA, et al. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 2005;52:219-24.
7. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-86.
8. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009;18:2071-7.
9. Cunninghame Graham DS, Graham RR, Manku H, et al. Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet 2008;40:83-9.
10. Chang YK, Yang W, Zhao M, et al. Association of BANK1 and TNFSF4 with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun 2009;10:414-20.
11. Mälarstig A, Eriksson P, Rose L, et al. Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolism. Clin Chem 2008;54:833-40.
12. Mälarstig A, Eriksson P, Rose L, et al. Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolism. Clin Chem 2008;54:833-40.
13. Olofsson PS, Söderström LA, Jern C, et al. Genetic variants of TNFSF4 and risk for carotid artery disease and stroke. J Mol Med 2009;87:337-46.
14. Wang X, Ria M, Kelmenson PM, et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005;37:365-72.
15. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91.
16. Reveille JD, Fischbach M, McNearney T, et al.; GENISOS Study Group. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30:332-46.
17. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610- 15.
18. Hua J, Kirou K, Lee C, et al. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-16.
19. Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006;45:694-702.
20. Graham RR, Kyogoku C, Sigurdsson S, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007;104:6758- 63.
21. Dieudé P, Guedj M, Wipff J, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009;60:225- 33.
22. Gourh P, Tan FK, Assassi S, et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anti-centromere antibody-positive systemic sclerosis. Arthritis Rheum 2006;54:3945-53.
23. Liakouli V, Manetti M, Pacini A, et al. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis 2009;68:584-90.
24. Kanemitsu S, Ihara K, Saifddin A, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002;29:1183-8.
25. Lee YH, Kim YR, Ji JD, et al. Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. J Rheumatol 2001;28:2008-11.
26. Mayes MD. The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis. Curr Rheumatol Rep 2000;2:512-16.
27. Arnett FC, Reveille JD, Goldstein R, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-60.
28. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
29. Hummers LK, Hall A, Wigley FM, et al. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 2009;36:576-82.
30. Assassi S, Arnett FC, Reveille JD, et al. Clinical, immunologic, and genetic features of familial systemic sclerosis. Arthritis Rheum 2007;56:2031-7.
31. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
32. Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980;69:520-6.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 1995;57:289-300.
34. Zhang H, Bonney G. Use of classification trees for association studies. Genet Epidemiol 2000;19:323-32.
35. Meyer OC, Fertig N, Lucas M, et al. Disease subsets, anti-nuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34:104-9.
36. Alkassab F, Gourh P, Tan FK, et al. An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anti-centromere antibody positive systemic sclerosis. Rheumatology (Oxford) 2007;46:1248-51.
37. Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 2006;78:464-79.
38. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271-85.
39. Jenkins SJ, Perona-Wright G, Worsley AG, et al. Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarising, signal for optimal Th-2 priming and memory induction in vivo. J Immunol 2007;179:3515-23.
40. Hoshino A, Tanaka Y, Akiba H, et al. Critical role for OX40 ligand in the development of pathogenic Th-2 cells in a murine model of asthma. Eur J Immunol 2003;33:861-9.
41. Li J, Li L, Shang X, et al. Negative regulation of IL-17 production by OX40/OX40L interaction. Cell Immunol 2008;253:31-7.
42. Xiao X, Kroemer A, Gao W, et al. OX40/OX40L costimulation affects induction of Foxp3+ regulatory T-cells in part by expanding memory T-cells in vivo. J Immunol 2008;181:3193-201.
43. Kato H, Kojima H, Ishii N, et al. Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunisations. J Clin Immunol 2004;24:237-48.
44. Stüber E, Neurath M, Calderhead D, et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995;2:507-21.
45. Stüber E, Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 1996;183:979-89.
46. Ito T, Amakawa R, Inaba M, et al. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol 2004;172:4253-9.
47. Murata K, Nose M, Ndhlovu LC, et al. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol 2002;169:4628-36.
48. Pakala SV, Bansal-Pakala P, Halteman BS, et al. Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions. Eur J Immunol 2004;34:3039-46.
49. Nohara C, Akiba H, Nakajima A, et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol 2001;166:2108-15.
50. Komura K, Yoshizaki A, Kodera M, et al. Increased serum soluble OX40 in patients with systemic sclerosis. J Rheumatol 2008;35:2359-62.
51. Reveille JD, Durban E, MacLeod-St Clair MJ, et al. Association of amino acid sequences in the HLA-DQB1 first domain with anti-topoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992;90:973-80.